{"id":"prasugrel-based-standard-dapt","safety":{"commonSideEffects":[{"rate":"1-5","effect":"Bleeding"},{"rate":"<0.1","effect":"Thrombotic thrombocytopenic purpura (TTP)"},{"rate":"1-3","effect":"Dyspnea"},{"rate":"1-2","effect":"Bradycardia"}]},"_chembl":{"chemblId":"CHEMBL1201772","moleculeType":"Small molecule","molecularWeight":"373.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prasugrel is a thienopyridine prodrug that is metabolized to an active metabolite, which irreversibly binds to the P2Y12 adenosine diphosphate receptor on platelets. This prevents platelet activation and aggregation. When combined with aspirin in a DAPT regimen, it reduces thrombotic cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.","oneSentence":"Prasugrel is a P2Y12 platelet receptor antagonist that irreversibly inhibits platelet aggregation as part of dual antiplatelet therapy (DAPT).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:02.789Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI)"},{"name":"Reduction of thrombotic cardiovascular events in patients with ACS"}]},"trialDetails":[{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT07025148","phase":"PHASE4","title":"Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)","status":"RECRUITING","sponsor":"University of Florida","startDate":"2025-10-01","conditions":"Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)","enrollment":40},{"nctId":"NCT05491200","phase":"PHASE4","title":"Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients","status":"RECRUITING","sponsor":"Research Maatschap Cardiologen Rotterdam Zuid","startDate":"2022-07-22","conditions":"ST Elevated Myocardial Infarction, Dual Antiplatelet Therapy","enrollment":1656}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Prasugrel based standard DAPT","genericName":"Prasugrel based standard DAPT","companyName":"Research Maatschap Cardiologen Rotterdam Zuid","companyId":"research-maatschap-cardiologen-rotterdam-zuid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prasugrel is a P2Y12 platelet receptor antagonist that irreversibly inhibits platelet aggregation as part of dual antiplatelet therapy (DAPT). Used for Acute coronary syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI), Reduction of thrombotic cardiovascular events in patients with ACS.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}